SXTP (60 Degrees Pharmaceuticals) 6-Month Share Buyback Ratio : -333.00% (As of Dec. 2024 )

View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals 6-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

6-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past six months, calculated as the percentage change in shares outstanding from two quarters ago to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. 60 Degrees Pharmaceuticals's current 6-Month Share Buyback Ratio was -333.00%.

Competitive Comparison of 60 Degrees Pharmaceuticals's 6-Month Share Buyback Ratio

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's 6-Month Share Buyback Ratio, along with its competitors' market caps and 6-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

60 Degrees Pharmaceuticals's 6-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's 6-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's 6-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

60 Degrees Pharmaceuticals 6-Month Share Buyback Ratio Calculation

60 Degrees Pharmaceuticals's 6-Month Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

6-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Jun. 2024 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Jun. 2024 )
	=	(0.203	-	0.879)	/	0.203
	=	-333.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

60 Degrees Pharmaceuticals (NAS:SXTP) 6-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

60 Degrees Pharmaceuticals 6-Month Share Buyback Ratio Related Terms

60 Degrees Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » 6-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036

Website

https://www.60degreespharma.com

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.

Executives

Cheryl Xu	director	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Geoffrey S Dow	director, 10 percent owner, officer: CEO and President	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Charles W Allen	director	1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209
Kentucky Technology Inc.	10 percent owner	824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511
Paul Field	director	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Tyrone Miller	officer: Chief Financial Officer	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Florida State University Research Foundation Inc.	10 percent owner	200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310
Bryan Lee Smith	officer: Chief Medical Officer	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Stephen Toovey	director	1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036